Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2014

Open Access 01-12-2014 | Editorial

Whether all obese subjects both in metabolic groups and non-metabolic groups should be treated or not

Authors: Moloud Payab, Shirin Hasani-Ranjbar, Bagher Larijani

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2014

Login to get access

Abstract

More recent researches have focused on metabolically healthy obese (MHO) phenotypes and on this phenotype, individuals may be obese without metabolic disorders. Osteoarthritis (OA), kidney diseases and sleep disorders are three factors related to the obesity that these conditions are associated only with obesity but not with metabolic complications. Regardless of whether obese individuals are in metabolic groups or not, they should be treated. All studies should be based on the risk of all-cause mortality in the MHO phenotypes.
Literature
1.
go back to reference Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organization technical report series 2000, 894: i-xii. 1–253 Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organization technical report series 2000, 894: i-xii. 1–253
2.
go back to reference Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET: Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004, 89(6):2569–2575. 10.1210/jc.2004-0165CrossRefPubMed Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET: Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004, 89(6):2569–2575. 10.1210/jc.2004-0165CrossRefPubMed
3.
go back to reference Koonce RC, Bravman JT: Obesity and osteoarthritis: more than just wear and tear. J Am Acad Orthop Surg 2013, 21(3):161–169. 10.5435/JAAOS-21-03-161PubMed Koonce RC, Bravman JT: Obesity and osteoarthritis: more than just wear and tear. J Am Acad Orthop Surg 2013, 21(3):161–169. 10.5435/JAAOS-21-03-161PubMed
4.
go back to reference Rtveladze K, Marsh T, Webber L, Kilpi F, Levy D, Conde W, et al.: Health and economic burden of obesity in Brazil. PLoS One 2013, 8(7):e68785. 10.1371/journal.pone.0068785CrossRefPubMedPubMedCentral Rtveladze K, Marsh T, Webber L, Kilpi F, Levy D, Conde W, et al.: Health and economic burden of obesity in Brazil. PLoS One 2013, 8(7):e68785. 10.1371/journal.pone.0068785CrossRefPubMedPubMedCentral
5.
6.
go back to reference Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, Garcia-Fuentes E, Almaraz MC, Colomo N, et al.: Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab 2013, 98(6):2318–2325. 10.1210/jc.2012-4253CrossRefPubMed Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, Garcia-Fuentes E, Almaraz MC, Colomo N, et al.: Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab 2013, 98(6):2318–2325. 10.1210/jc.2012-4253CrossRefPubMed
7.
go back to reference Sims EA: Are there persons who are obese, but metabolically healthy? Metab Clin Exp 2001, 50(12):1499–1504. 10.1053/meta.2001.27213CrossRefPubMed Sims EA: Are there persons who are obese, but metabolically healthy? Metab Clin Exp 2001, 50(12):1499–1504. 10.1053/meta.2001.27213CrossRefPubMed
8.
go back to reference Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al.: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168(15):1609–1616. 10.1001/archinte.168.15.1609CrossRefPubMed Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al.: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168(15):1609–1616. 10.1001/archinte.168.15.1609CrossRefPubMed
9.
go back to reference Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al.: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008, 168(15):1617–1624. 10.1001/archinte.168.15.1617CrossRefPubMed Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al.: The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008, 168(15):1617–1624. 10.1001/archinte.168.15.1617CrossRefPubMed
10.
go back to reference Karelis AD, Rabasa-Lhoret R: Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab 2008, 34(2):183–184. 10.1016/j.diabet.2007.11.004CrossRefPubMed Karelis AD, Rabasa-Lhoret R: Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab 2008, 34(2):183–184. 10.1016/j.diabet.2007.11.004CrossRefPubMed
11.
go back to reference Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, et al.: Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013, 36(8):2388–2394. 10.2337/dc12-1971CrossRefPubMedPubMedCentral Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, et al.: Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 2013, 36(8):2388–2394. 10.2337/dc12-1971CrossRefPubMedPubMedCentral
12.
go back to reference National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. Obes Res 1998, 6(2):51S-209S. National Institutes of Health: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. Obes Res 1998, 6(2):51S-209S.
13.
go back to reference Hamer M, Stamatakis E: Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012, 97(7):2482–2488. 10.1210/jc.2011-3475CrossRefPubMedPubMedCentral Hamer M, Stamatakis E: Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012, 97(7):2482–2488. 10.1210/jc.2011-3475CrossRefPubMedPubMedCentral
Metadata
Title
Whether all obese subjects both in metabolic groups and non-metabolic groups should be treated or not
Authors
Moloud Payab
Shirin Hasani-Ranjbar
Bagher Larijani
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2014
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/2251-6581-13-21

Other articles of this Issue 1/2014

Journal of Diabetes & Metabolic Disorders 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.